All In Biotech

Drug Trial Radar · NCT07371650

This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza

A Multicenter, Open-Label, Randomized Phase 2a Study to Evaluate the Safety and Efficacy of Different Oral Doses of TRX-100 and Standard of Care in Participants With Influenza

Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

105

Planned (sponsor's estimate)

Start

Dec 15, 2025

Primary completion

Dec 2026

Study completion Jan 2027

Sponsor

Lead sponsor
Traws Pharma, Inc.Industry
Sponsor type
Industry
First posted
Jan 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an early-stage clinical trial to determine a safe and effective dose for Tivoxavir Marboxil (TRX-100) in patients with mild to moderate Influenza. Participants will take a study drug as well as a standard therapy. A descriptive statistics will be used to present the study results.

Conditions

  • Influenza

Interventions

  • TRX-100Drug

    CEN inhibitor, dosage form - capsules, dosing regimen - QD

  • Standard of Care (SOC)Drug

    Standard of Care Influenza Antiviral therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of AE/SAETime frame: up to Day 28
  2. Incidence of abnormal laboratory tests resultsTime frame: Up to Day 28
  3. Incidence of abnormal clinically significant ECG resultsTime frame: Up to 28 days
  4. Number of participants with abnormal physical examinations findingsTime frame: Up to 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Novatrials

    Charlestown, New South Wales, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.